Clovis Oncology Stock Cash And Equivalents
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology fundamentals help investors to digest information that contributes to Clovis Oncology's financial success or failures. It also enables traders to predict the movement of Clovis Stock. The fundamental analysis module provides a way to measure Clovis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clovis Oncology stock.
Clovis |
Clovis Oncology Company Cash And Equivalents Analysis
Clovis Oncology's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Clovis Oncology Cash And Equivalents | 94.58 M |
Most of Clovis Oncology's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Clovis Oncology has 94.58 M in Cash And Equivalents. This is 88.48% lower than that of the Biotechnology sector and 78.85% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 96.5% higher than that of the company.
Clovis Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clovis Oncology's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clovis Oncology could also be used in its relative valuation, which is a method of valuing Clovis Oncology by comparing valuation metrics of similar companies.Clovis Oncology is currently under evaluation in cash and equivalents category among its peers.
Clovis Fundamentals
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 148.76 M | |||
| Gross Profit | 115.3 M | |||
| EBITDA | (224.76 M) | |||
| Net Income | (264.52 M) | |||
| Cash And Equivalents | 94.58 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 436.77 M | |||
| Debt To Equity | 810.00 % | |||
| Current Ratio | 1.17 X | |||
| Book Value Per Share | (2.89) X | |||
| Cash Flow From Operations | (196.06 M) | |||
| Short Ratio | 4.63 X | |||
| Earnings Per Share | (2.08) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 413 | |||
| Beta | 0.22 | |||
| Market Capitalization | 11.77 M | |||
| Total Asset | 472.83 M | |||
| Retained Earnings | (2.3 B) | |||
| Working Capital | 464.12 M | |||
| Current Asset | 539.7 M | |||
| Current Liabilities | 75.58 M | |||
| Z Score | -5.6 | |||
| Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |